We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Relationship between bleeding episodes, health‐related quality of life and direct costs in adults with severe haemophilia A: Secondary analyses from the CHESS study.
- Authors
O'Hara, Jamie; Noone, Declan; Watt, Maureen
- Abstract
This suggests that new approaches may be required to assess the cumulative impact of bleeds in patients with haemophilia over time, whereby even a single minor bleed could have a deleterious effect on a patient's HRQoL. Keywords: Cost of illness; haemophilia A; healthcare economics; quality of life; surveys and questionnaires EN Cost of illness haemophilia A healthcare economics quality of life surveys and questionnaires e117 e120 4 09/13/22 20220901 NES 220901 The prevalence of significant morbidities and the high cost of care associated with severe haemophilia A contribute to both impaired health-related quality of life (HRQoL) for patients and significant financial impact on healthcare budgets.1-3 Findings from CHESS (Cost of Haemophilia across Europe - a Socioeconomic Survey), a questionnaire-based cost-of-illness survey in patients with haemophilia A and B in five European countries (France, Germany, Italy, Spain and the United Kingdom), revealed the total annual cost of severe haemophilia in 2014 was €1.55 billion (just under €200,000 per patient), driven by consumption of clotting factor replacement therapy.4 Estimated total indirect costs, driven by patient and caregiver work loss, were €43.3 million (€6075 per patient). ABR, annualised bleeding rate; SD, standard deviation gl We evaluated drug-related and non-drug-related direct costs associated with bleeding episodes in the 947 patients with severe haemophilia A. In the evaluable population, mean (standard deviation) annual per-patient drug-related and non-drug-related direct costs associated with any bleeding episodes were €192,913 (€181,578) and €8253 (€13,810), respectively, compared with €129,536 (€127,310) and €3909 (€7853), respectively, for patients with no recorded bleeding episodes.
- Subjects
QUALITY of life; DIRECT costing; HEMOPHILIA; SECONDARY analysis; HEMORRHAGE
- Publication
Haemophilia, 2022, Vol 28, Issue 5, pe117
- ISSN
1351-8216
- Publication type
Article
- DOI
10.1111/hae.14616